Second-Chance cell therapy for myeloma patients

NCT ID NCT04771078

First seen Jan 11, 2026 · Last updated Jun 10, 2026 · Updated 19 times

Summary

This program offers a special type of cell therapy (ide-cel) to people with multiple myeloma whose manufactured treatment batch didn't meet commercial standards but may still be safe and effective. Participants must be clinically stable and have no other suitable treatment options. The goal is to control the disease, not cure it, and patients will need ongoing monitoring.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.